Back to News
Market Impact: 0.5

Stocks making the biggest moves premarket: Block, Pinterest, Verizon and more

ALKSQHESCVXPINSMSBCSDLTRTGTDPZCLFVZSRPTMFGIVZQQQ
Market Technicals & FlowsCompany FundamentalsCorporate EarningsAnalyst InsightsRegulation & LegislationFintechHealthcare & BiotechM&A & Restructuring
Stocks making the biggest moves premarket: Block, Pinterest, Verizon and more

Pre-market trading was marked by significant movements, with Block surging 10% ahead of its S&P 500 inclusion and Domino's Pizza gaining 4% on its first U.S. same-store sales beat in five quarters. Verizon and Cleveland-Cliffs also rose on better-than-expected Q2 results, while Pinterest and Invesco received analyst upgrades. Conversely, Sarepta Therapeutics plummeted 8% after the FDA withdrew support for its gene therapy following a patient death, and Target declined over 1% on an analyst downgrade citing anticipated sales underperformance.

Analysis

Pre-market activity reveals a market highly responsive to company-specific catalysts, including earnings reports, analyst rating changes, and significant corporate developments. On the positive side, Block (SQ) surged 10% based on a technical factor—its impending inclusion in the S&P 500—rather than new fundamental data. Strong operational results drove gains in other sectors, with Verizon (VZ) rising 5% on an earnings and revenue beat, and Cleveland-Cliffs (CLF) gaining 7% after posting a narrower-than-expected Q2 loss. Domino's Pizza (DPZ) saw a nearly 4% increase after its 3.4% same-store sales growth beat estimates for the first time in five quarters, though its earnings miss adds a note of caution. Analyst upgrades were a key driver for Pinterest (PINS), which jumped over 5% on a Morgan Stanley upgrade citing valuation and monetization improvements, and for Invesco (IVZ), which rose 2% after TD Cowen called its QQQ fund restructuring a "game changing event." Conversely, significant negative catalysts punished specific stocks. Sarepta Therapeutics (SRPT) plummeted 8% after the FDA withdrew support for its gene therapy, Elevidys, following a patient death, triggering a wave of analyst downgrades. In retail, a clear divergence emerged as Barclays upgraded Dollar Tree (DLTR) while downgrading Target (TGT) on expectations of continued sales underperformance, causing Target's shares to fall over 1%.

AllMind AI Terminal